1226 related articles for article (PubMed ID: 24075771)
1. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
2. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
Fialkow J
Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
[TBL] [Abstract][Full Text] [Related]
4. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
5. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
Singh S; Arora RR; Singh M; Khosla S
Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
[TBL] [Abstract][Full Text] [Related]
6. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
Harris WS; Dayspring TD; Moran TJ
Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
[TBL] [Abstract][Full Text] [Related]
7. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
8. Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3.
Pirillo A; Catapano AL
Drug Des Devel Ther; 2015; 9():2129-37. PubMed ID: 25914523
[TBL] [Abstract][Full Text] [Related]
9. Icosapent ethyl for the treatment of hypertriglyceridemia.
Ballantyne CM; Braeckman RA; Soni PN
Expert Opin Pharmacother; 2013 Jul; 14(10):1409-16. PubMed ID: 23701295
[TBL] [Abstract][Full Text] [Related]
10. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Backes J; Anzalone D; Hilleman D; Catini J
Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
[TBL] [Abstract][Full Text] [Related]
11. Overview of omega-3 Fatty Acid therapies.
Bradberry JC; Hilleman DE
P T; 2013 Nov; 38(11):681-91. PubMed ID: 24391388
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 fatty acids for cardioprotection.
Lee JH; O'Keefe JH; Lavie CJ; Marchioli R; Harris WS
Mayo Clin Proc; 2008 Mar; 83(3):324-32. PubMed ID: 18316000
[TBL] [Abstract][Full Text] [Related]
13. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
14. History and future of omega-3 fatty acids in cardiovascular disease.
Sperling LS; Nelson JR
Curr Med Res Opin; 2016; 32(2):301-11. PubMed ID: 26566071
[TBL] [Abstract][Full Text] [Related]
15. Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol.
Sharp RP; Gales BJ; Sirajuddin R
Am J Cardiovasc Drugs; 2018 Apr; 18(2):83-92. PubMed ID: 29080985
[TBL] [Abstract][Full Text] [Related]
16. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians.
Bays H
Drugs Today (Barc); 2008 Mar; 44(3):205-46. PubMed ID: 18536782
[TBL] [Abstract][Full Text] [Related]
17. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
Weintraub HS
Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
[TBL] [Abstract][Full Text] [Related]
18. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids.
Kris-Etherton PM; Richter CK; Bowen KJ; Skulas-Ray AC; Jackson KH; Petersen KS; Harris WS
Methodist Debakey Cardiovasc J; 2019; 15(3):171-178. PubMed ID: 31687095
[TBL] [Abstract][Full Text] [Related]
19. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
Hobbs T; Caso R; McMahon D; Nymark M
Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same.
Gutstein AS; Copple T
J Am Assoc Nurse Pract; 2017 Dec; 29(12):791-801. PubMed ID: 29280361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
